Pay in 4 interest-free payments of $37.50 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
producing high-avidity binding that substantially exceeds the affinity of monovalent GalNAc ligands and closely mimics the geometry of clinically validated Tri-GalNAc targeting moieties used in approved GalNAc-siRNA therapeutics
N-α-Fmoc-O-(hepta-O-acetyl-α-D-mannopyranosyl-α(1-2)-D-mannopyranosyl)-L-threonine
enabling straightforward spectrophotometric assays of enzyme activity in solution and in high-throughput screening formats
144) / Mucin1
C71H118N18O30 / 1703
GP100075: MUC1(126-149-Cys)-Tn(131,144) Pack Size:1 mg producing high-avidity binding that substantiallyC114H180N32O43S 2718. 9 MUC1 synthetic glycopeptide. Glycosylated Mucin 1 (MUC1) peptide fragment containing amino acid sequence Pro126Gly149 (24 AA in length) from the tandem repeat (TR) region of the MUC1 protein. The fragment contains tumor associated carbohydrate antigen (TACA), Tn antigen, O glycosylation ( GalNAc) at Thr131 and Thr144. The C terminus Cysteine (amide) allows for conjugation to maleimide functionalized carrier proteins. MUC1(126
